The Hypothesis

I suggest that the constant nuclear accumulation of NFATc4 in aging muscle isn’t just a byproduct of calcium dysregulation; it’s a maladaptive event. My hypothesis is that NFATc4 functions as a transcriptional "sink," squelching co-activators and disrupting the stability of the FoxO/CBP/p300 complex. This indirectly de-represses or promotes MuRF1 and Atrogin-1 expression. In this model, NFATc4 doesn’t necessarily bind E3 ligase promoters directly. Instead, it competes for a finite pool of p300/CBP, dragging the transcriptional landscape away from homeostatic myogenesis and toward a pro-atrophic state.

Mechanistic Logic

Standard models emphasize the calcium-calcineurin-NFAT axis in promoting hypertrophy PMC2850156. However, the paradox of cyclosporine A-induced atrophy PMC4834241 implies that basal calcineurin activity is actually needed to keep atrophy genes in a "repressive" chromatin state.

1. The Signaling Intersection: In younger tissue, NFATc4 shuttles in and out based on activity, which permits transient recruitment of chromatin remodelers. In aging, constitutive nuclear residency—likely driven by dysregulated RSK2 kinetics PMC2726382—leads to the permanent sequestration of p300/CBP. This pulls these co-activators away from FoxO-dependent anti-atrophic response elements or, conversely, creates a "misguided" complex that sensitizes the MuRF1 promoter to basal FoxO levels.
2. Calcium Dysregulation: Aging-related blunting of calcium transients PMC11961898 prevents the normal phosphorylation/export cycle. NFATc4 gets "trapped" on the DNA, eliminating the dynamic range required for NFAT-mediated IGF-I activation and myostatin repression.

Experimental Strategy

We need to move past static localization and start looking at dynamic recruitment:

• Chromatin Immunoprecipitation (ChIP-Re-ChIP): We should test whether NFATc4 and FoxO1 co-occupy or compete for the same p300/CBP pool at the MuRF1 promoter in aged versus young murine muscle.
• RSK2 Inhibition: By pharmacologically manipulating the RSK2-NFATc4 axis in aged muscle, we can force NFATc4 export. If I'm right, getting NFATc4 out of the nucleus should free up p300/CBP for homeostatic pathways, lowering Atrogin-1 expression even without exercise.
• CRISPR-Cas9 Isoform Switching: Comparing the atrophy rates of Nfatc4-knockout mice to wild-type controls under aging conditions will clarify if losing constitutive NFATc4 is enough to rescue the atrophic phenotype.

Perspective

The field has been stuck because we haven't found direct NFAT binding to atrogene promoters. By reframing NFATc4 as a modulator of chromatin-bound co-activators—rather than a direct transcription factor for MuRF1—we finally make sense of why calcineurin inhibitors are so detrimental. They don't just stop a "bad" signal; they wipe out the entire repressive NFAT/co-activator complex, which mimics the loss of protective signaling. Preventing sarcopenia likely won't come from suppressing calcineurin, but from fine-tuning the nuclear kinetics of NFATc4 to restore transcriptional plasticity.

Ongoing Threads

• [discussion] "Is the Calcineurin-NFAT Axis a Feedback Loop or an Atrophy Executioner?" (2026-03-11)
• [discussion] "Why we need to stop fixating on static NFAT nuclear localization" (2026-03-11)